A 2010 law that created a fast track for approving biosimilar drugs just got a boost toward the U.S. Supreme Court. In early December, the solicitor general recommended that the high court review the Biologics Price Competition and Innovation Act (BPCIA). The 2010 law established a complex series of disclosures, known as the patent dance, between branded biologic drugmakers and companies that want to market less expensive biosimilar versions. We asked Goodwin Procter partner Elaine Herrmann Blais, editor of the firm’s Big Molecule Watch blog, for an update.
Q. Why is this law important?
